Phase 4 N=12 Double-blind Basic Science

Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion

Healthy · Type 2 Diabetes

Bottom Line

View on ClinicalTrials.gov: NCT00885638 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2013

Primary outcome: Primary: Glucagon-like Peptide-1 Secretion After Meal Ingestion — 0.82; 1.24 nmol/l/min

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Sitagliptin (Drug); placebo (Drug)
Age: Adult · 20+ yrs
Sex: Male
Sponsor: Lund University
Primary completion: May 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Glucagon-like Peptide-1 Secretion After Meal Ingestion	0.82; 1.24	—
SECONDARY Insulin Secretion After Ingestion of Meal	29.6; 24.7	—

Summary

The regulation by DPP-4 inhibition after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).

Eligibility Criteria

Inclusion Criteria

Healthy men
Age 20-30 years
BMI 20-30 kg/m2

Exclusion Criteria

Any disease
Any medication

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00885638). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.